Trial Profile
Effect of gamma-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Semagacestat (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms IDENTITY
- Sponsors Eli Lilly and Company
- 25 Jul 2013 Primary endpoint 'Alzheimer's-Disease-Cooperative-Study-Activities-of-Daily-Living-Inventory' has not been met.
- 25 Jul 2013 Primary endpoint 'Alzheimer's-Disease-Assessment-Scale-cognitive-subpart' has not been met.
- 21 Mar 2012 Additional location (Greece) added as reported by European Clinical Trials Database.